Barinthus Biotherapeutics

NASDAQ: BRNS · Real-Time Price · USD
1.13
0.01 (0.89%)
At close: May 01, 2025, 3:59 PM
1.09
-3.50%
Pre-market: May 02, 2025, 08:10 AM EDT

Company Description

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer.

It is advancing a pipeline of product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer; and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer.

The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023.

Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Harwell, the United Kingdom.

Barinthus Biotherapeutics
Barinthus Biotherapeutics logo
Country GB
IPO Date Apr 30, 2021
Industry Biotechnology
Sector Healthcare
Employees 105
CEO William J. Enright MBA

Contact Details

Address:
Zeus Building
Harwell,
GB
Website https://www.barinthusbio.com

Stock Details

Ticker Symbol BRNS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001828185
CUSIP Number n/a
ISIN Number US91864C1071
Employer ID 00-0000000
SIC Code 2834

Key Executives

Name Position
William J. Enright MBA Chief Executive Officer & Director

Latest SEC Filings

Date Type Title
Apr 25, 2025 ARS Filing
Apr 25, 2025 DEFA14A Filing
Apr 25, 2025 DEF 14A Filing
Mar 20, 2025 S-8 Filing
Mar 20, 2025 10-K Annual Report
Mar 20, 2025 8-K Current Report
Feb 11, 2025 SCHEDULE 13G/A [Amend] Filing
Feb 05, 2025 4 Filing
Feb 05, 2025 4 Filing
Feb 05, 2025 4 Filing